항핵항체의 올바른 해석
Interpretation of Anti-Nuclear Antibody Tests
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Anti-nuclear antibodies (ANAs) are autoantibodies against nuclear substances or other cellular components. ANA tests are used in the diagnostic process to screen patients with suspected rheumatic or autoimmune diseases. ANA-associated diseases are characterized by a high titer of antinuclear antibodies and include systemic lupus erythematosus, systemic sclerosis, and mixed connective tissue diseases. ANA test results must be cautiously interpreted as they can be positive not only in infections and oncological diseases but also for the healthy general population. The ANA test mainly uses the indirect immunofluorescence test, and the results are expressed in terms of the final titer and pattern. The ANA test can increase diagnostic value when used in conjunction with the evaluation of disease-related clinical symptoms.
Abstract
Anti-nuclear antibodies (ANAs) are autoantibodies against nuclear substances or other cellular components. ANA tests are used in the diagnostic process to screen patients with suspected rheumatic or autoimmune diseases. ANA-associated diseases are characterized by a high titer of antinuclear antibodies and include systemic lupus erythematosus, systemic sclerosis, and mixed connective tissue diseases. ANA test results must be cautiously interpreted as they can be positive not only in infections and oncological diseases but also for the healthy general population. The ANA test mainly uses the indirect immunofluorescence test, and the results are expressed in terms of the final titer and pattern. The ANA test can increase diagnostic value when used in conjunction with the evaluation of disease-related clinical symptoms.
참고문헌 (15)
- Agmon-Levin N, "International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies", Ann Rheum Dis, 73, pp.17~23 (2014)
- Pisetsky DS, "Antinuclear antibody testing-misunderstood or misbegotten?", Nat Rev Rheumatol, 13, pp.495~502 (2017)
- Kavanaugh A, "Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists", Arch Pathol Lab Med, 124, pp.71~81 (2000)
- Hoffman IE, "Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests", Clin Chem, 48, pp.2171~2176 (2002)
- Tan EM, "A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity", Arthritis Rheum, 42, pp.455~464 (1999)
- Aringer M, "2019 European League Against Rheumatism", American College of Rheumatology classification criteria for systemic lupus erythematosus, 2019, pp.78, 1151~1159
- Abeles AM, "The clinical utility of a positive antinuclear antibody test result", Am J Med, 126, pp.342~348 (2013)
- Mariz HA, "Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases", Arthritis Rheum, 63, pp.91~200 (2011)
- Hoffman IE, "Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus", Ann Rheum Dis, 63, pp.1155~1158 (2004)
- Meroni PL, "ANA screening : an old test with new recommendations", Ann Rheum Dis, 69, pp.1420~1422 (2010)
- Gunawardena H, "The clinical features of myositis-associated autoantibodies : a review", Clin Rev Allergy Immunol, 52, pp.45~57 (2017)
- Schulte-Pelkum J, "Latest update on the Ro", SS-A autoantibody system, 2009, pp.8, 632~637
- Ching KH, "Two major autoantibody clusters in systemic lupus erythematosus", PLoS One, 7, pp.e32001~ (2012)
- Gunnarsson R, "Mixed connective tissue disease", Best Pract Res Clin Rheumatol, 30, pp.95~111 (2016)
- Fritzler MJ, "Choosing wisely : review and commentary on anti-nuclear antibody(ANA)testing", Autoimmun Rev, 15, pp.272~280 (2016)